Then, IL-38 and IL-36RA bind to IL-36R and inhibit inflammation in the psoriasis microenvironment, holding promising immune gene-based therapeutic capabilities of IL-38 and IL-36RA for psoriatic patients [135]. The gene discussed is IL1RL2; the disease is psoriasis.